Combining a targeted radiotherapy and gene therapy approach for adenocarcinoma of prostate (original) (raw)

• Weir HK et al. Annual report to the nation on the status of cancer, 1975–2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 2003; 95: 1276–1299.
  Article Google Scholar
• Duchesne GM . Radiation for prostate cancer. Lancet Oncol 2001; 2: 73–81.
  Article CAS Google Scholar
• Peschel RE, Colberg JW . Surgery, brachytherapy, and external-beam radiotherapy for early prostate cancer. Lancet Oncol 2003; 4: 233–241.
  Article Google Scholar
• Marks LB, Carroll PR, Dugan TC, Anscher MS . The response of the urinary bladder, urethra, and ureter to radiation and chemotherapy. Int J Radiat Oncol Biol Phys 1995; 31: 1257–1280.
  Article CAS Google Scholar
• Gaze MN, Wheldon TE . Radiolabelled mIBG in the treatment of neuroblastoma. Eur J Cancer 1996; 32A: 93–96.
  Article CAS Google Scholar
• Troncone L, Rufini V . 131I-MIBG therapy of neural crest tumours (review). Anticancer Res 1997; 17: 1823–1831.
  CAS PubMed Google Scholar
• Mukherjee JJ et al. Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with 131I-meta-iodobenzylguanidine ([131I]MIBG). Clin Endocrinol (Oxf) 2001; 55: 47–60.
  Article CAS Google Scholar
• Boyd M et al. Noradrenaline transporter gene transfer for radiation cell kills by [131I]metaiodobenzylguanidine. Gene Therapy 1999; 6: 1147–1152.
  Article CAS Google Scholar
• Boyd M et al. A gene therapy/targeted radiotherapy strategy for radiation cell kill by [131I]metaiodobenzylguanidine. J Gene Med 2001; 3: 165–172.
  Article CAS Google Scholar
• Mairs RJ, Cunningham SH, Boyd M, Carlin S . Applications of gene transfer to targeted radiotherapy. Cur Pharm Des 2000; 6: 1419–1432.
  Article CAS Google Scholar
• Boyd M et al. Expression in UVW glioma cells of the noradrenaline transporter gene, driven by the telomerase RNA promoter, induces active uptake of [131I]MIBG and clonogenic cell kill. Oncogene 2001; 20: 7804–7808.
  Article CAS Google Scholar
• Plumb JA et al. Telomerase specific suicide gene therapy vectors expressing bacterial nitroreductase sensitise human cancer cells to the pro-drug CB1954. Oncogene 2001; 20: 7797–7803.
  Article CAS Google Scholar
• Sommerfeld HJ et al. Telomerase activity: a prevalent marker of malignant human prostate tissue. Cancer Res 1996; 56: 218–222.
  CAS PubMed Google Scholar
• Lin Y et al. Telomerase activity in primary prostate cancer. J Urol 1997; 157: 1161–1165.
  Article CAS Google Scholar
• Shay JW, Bacchetti . A survey of telomerase activity in human cancer. Eur J Cancer 1997; 33: 787–791.
  Article CAS Google Scholar
• Kim NW, Hruszkewycz AM . Telomerase activity modulation in the prevention of prostate cancer. Urology 2001; 57 (Suppl. 4A): 148–153.
  Article CAS Google Scholar
• Orlando C, Gelmini S, Selli C, Pazzagli M . Telomerase in urological malignancy. J Urol 2001; 166: 666–673.
  Article CAS Google Scholar
• Orlando C, Gelmini S . Telomerase in endocrine and endocrine-dependent tumours. J Steroid Biochem Mol Biol 2001; 78: 201–214.
  Article CAS Google Scholar
• Essand M, Groenvik C, Hartman T, Carlsson J . Radioimmunotherapy of prostatic adenocarcinomas: effects of 131I-labelled E4 antibodies on cells at different depth in DU 145 spheroids. Int J Cancer 1995; 6: 387–394.
  Article Google Scholar
• Ballangrud AM et al. Growth and characterization of LNCaP prostate cancer cell spheroids. Clin Canc Res (Suppl) 1999; 5: 3171s–3176s.
  CAS Google Scholar
• Hedlund TE, Duke RC, Miller GJ . Three-dimensional spheroid cultures of human prostate cancer cell lines. Prostate 1999; 41: 154–165.
  Article CAS Google Scholar
• Boyd M et al. Transfectant mosaic spheroids: a new model for evaluation of bystander effects in experimental gene therapy. J Gene Med 2002; 4: 1–10.
  Article Google Scholar
• Cunningham S et al. A gene therapy approach to enhance the targeted radiotherapy of neuroblastoma. Med Pediatr Oncol 2000; 35: 708–711.
  Article CAS Google Scholar
• Steiner MS, Gingrich JR . Gene therapy for prostate cancer: where are we now? J Urol 2000; 164: 1121–1136.
  Article CAS Google Scholar
• Maitland NJ . Targeting therapeutic gene expression to human prostate cancers. Curr Opin Mol Ther 2000; 2: 389–399.
  CAS PubMed Google Scholar
• Koeneman KS, Hsieh J-T . The prospect of gene therapy for prostate cancer: update on theory and status. Curr Opin Urol 2001; 11: 489–494.
  Article CAS Google Scholar
• McKenzie KE, Umbricht CE, Saraswati S . Applications of telomerase research in the fight against cancer. Mol Med Today 1999; 5: 114–122.
  Article CAS Google Scholar
• Urquidi V, Tarin D, Goodison S . Role of telomerase in cell senescence and oncogenesis. Ann Rev Med 2000; 51: 65–79.
  Article CAS Google Scholar
• Keith WN, Evans TRJ, Glasspool RM . Telomerase and cancer: time to move from a promising target to a clinical reality. J Pathol 2001; 195: 404–414.
  Article CAS Google Scholar
• Boyd M et al. An efficient targeted radiotherapy/gene therapy strategy utilising human telomerase promoters and radioastatine and harnessing radiation mediated bystander effects. J Gene Med 2004; 6: 937–947.
  Article CAS Google Scholar
• Spitzweg C et al. Prostate-specific antigen (PSA) promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines. Cancer Res 1999; 59: 2136–2141.
  CAS PubMed Google Scholar
• Lee SE et al. Development of a new plasmid vector with PSA-promoter and enhancer expressing tissue-specificity in prostate carcinoma cell lines. Anticancer Res 2000; 20: 417–422.
  CAS PubMed Google Scholar
• Djordjevic B . Bystander effects: a concept in need of clarification. BioEssays 2000; 22: 286–290.
  Article CAS Google Scholar
• Belyakov OV et al. Direct evidence for a bystander effect of ionising radiation in primary human fibroblasts. Br J Cancer 2001; 84: 674–679.
  Article CAS Google Scholar
• Hall EJ . The bystander effect. Health Phys 2003; 85: 31–35.
  Article CAS Google Scholar
• Wheldon TE, O'Donoghue JA, Barrett A, Michalowski AS . The curability of tumours of differing size by targeted radiotherapy using 131I or 90Y. Radiother Oncol 1991; 21: 91–99.
  Article CAS Google Scholar
• Gaze MN et al. [131I]meta-iodobenzylguanidine therapy in neuroblastoma spheroids of different sizes. Br J Cancer 1992; 66: 1048–1052.
  Article CAS Google Scholar
• Cunningham SH et al. Toxicity to neuroblastoma cells and spheroids of benzylguanidine conjugated to radionuclides with short-range emissions. Br J Cancer 1998; 77: 2061–2068.
  Article CAS Google Scholar
• Allen BJ . Targeted alpha therapy: Evidence for potential efficacy of alpha-immunoconjugates in the management of micrometastatic cancer. Australas Radiol 1999; 43: 480–486.
  Article CAS Google Scholar
• Zalutsky MR, G . Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha-particle radiotherapy. Curr Pharm Des 2000; 6: 1433–1455.
  Article Google Scholar
• Imam SK . Advancements in cancer therapy with alpha-emitters: a review. Int J Radiat Oncol Biol Phys 2001; 51: 271–278.
  Article CAS Google Scholar
• Jurcic JG et al. Targeted α particle immunotherapy for myeloid leukaemia. Blood 2002; 100: 1233–1239.
  CAS PubMed Google Scholar